Recruitment of individuals primed during childhood with TdaP (tetanus, diphtheria , acellular pertussis) vaccine, and administration of an Adacel booster with blood sample collection at various time points before and after vaccination. Collection of blood sample volumes will be large enough to allow assessment and comparison of multiple assays that evaluate cell-mediated immune (CMI) responses and other biomarkers following the administration of pertussis vaccinations. The ultimate objective would be to utilize these validated assays for evaluation of pertussis clinical trial results or development of new pertussis vaccine formulations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Determine best assay to evaluate CMI responses post-vaccination: CD4 T-cell proliferation
Timeframe: Days -14 to 28
Determine best assay to evaluate CMI responses post-vaccination: CD8 T-cell proliferation
Timeframe: Days -14 to 28
Determine optimal time point for sample collection: CD4 T-cell responses
Timeframe: Days -14 to 28
Determine optimal time point for sample collection: CD8 T-cell responses
Timeframe: Days -14 to 28